Autoantibody profiling for the study and treatment of autoimmune disease
1 Department of Medicine, Division of Rheumatology and Immunology, Stanford University School of Medicine, Stanford, California, USA
2 Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA
3 Tolerion, Palo Alto, California, USA
Arthritis Res 2002, 4:290-295 doi:10.1186/ar426Published: 7 May 2002
Proteomics technologies enable profiling of autoantibody responses using biological fluids derived from patients with autoimmune disease. They provide a powerful tool to characterize autoreactive B-cell responses in diseases including rheumatoid arthritis, multiple sclerosis, autoimmune diabetes, and systemic lupus erythematosus. Autoantibody profiling may serve purposes including classification of individual patients and subsets of patients based on their 'autoantibody fingerprint', examination of epitope spreading and antibody isotype usage, discovery and characterization of candidate autoantigens, and tailoring antigen-specific therapy. In the coming decades, proteomics technologies will broaden our understanding of the underlying mechanisms of and will further our ability to diagnose, prognosticate and treat autoimmune disease.